Targeting the receptor for epidermal growth factor receptor (EGFR) has been rewarding in cancer and many pharmaceuticals are approved alone or in combination with chemotherapy for colorectal cancer, non-small-cell lung cancer, and pancreatic cancer, among others, but not for gliomas (9). This evidence concerns the gene EGFR and central nervous system cancer.